Skip to main content

Table 1 Sample distribution according to the demographic and clinical variables of individuals with cancer

From: Oestrogen receptor beta isoform expression in sporadic colorectal cancer, familial adenomatous polyposis and progressive stages of colorectal cancer

Variable Category Frequency (%)
N = 98
Gender Male 53 (54.1)
Female 45 (45.9)
Age (years) Variation 41–88
Median 58.6
Mean (Standard Deviation) 65.45 (10.2)
Age range (years) ≤65 52 (53.1)
>65 46 (46.9)
Location Proximal 30 (30.6)
Distal 68 (69.4)
Topography Colon 82 (83.7)
Upper rectal 16 (16.3)
Follow-up time (months) Variation (months) 1.7–188.7
Median 58.6
Mean (Standard Deviation) 70.15 (42.3)
Status Living without disease 78 (79.5)
Living with disease 2 (2.04)
Death from other causes 3 (3.06)
Death from disease 15 (15.3)
Recurrence No recurrence 77 (78.5)
Local 1 (1.02)
Liver 13 (13.2)
Lung 4 (4.08)
Peritoneum 3 (3.0)
T Stage T1/T2 48 (48.9)
T3/T4 50 (51.1)
N Stage N0 58 (59.2)
N+ 40 (40.8)
Overall TNM stage S I 39 (39.8)
S II 18 (18.4)
S III 27 (27.6)
S IV 14 (14.3)
Histological grade Well differentiated (G1) 08 (8.2)
Moderately differentiated (G2) 84 (85.7)
Poorly differentiated (G3) 06 (6.3)
Blood embolization No 95 (96.9)
Yes 3 (3.1)
Perineural invasion No 89 (90.8)
Yes 9 (9.20)
Lymphatic embolization No 85 (86.7)
Yes 13 (13.3)
Adjuvant chemotherapy No 52 (53.7)
Yes 46 (46.7)
Adjuvant CT scheme No chemotherapy treatment 52 (53.7)
FOLFOX 28 (28.5)
5 FU + LV 07 (7.14)
FOLFOX/FOLFIRI + Bevacizumab 05 (5.10)
FOLFIRI + Cetuximab 1 (1.02)
XELODA/XELOX 5 (5.10)
  1. CT chemotherapy, 5-FU + LV 5-Fluorouracil + Leucovorin (folinic acid), FOLFOX Leucovorin + Oxaliplatin + Oxaliplatin, FOLFIRI Fluorouracil + Leucovorin + Irinotecan, XELODA/XELOX Capecitabine combined with Oxaliplatin